CHAC-WT:NSD-Chardan Healthcare Acquisition Corp

COMMON STOCK | Others |

Last Closing

USD 0.79

Change

-0.01 (-1.25)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-09-19 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
QQQM Invesco NASDAQ 100 ETF

-0.97 (-0.55%)

USD 22.08B
ACWI iShares MSCI ACWI ETF

-0.15 (-0.14%)

USD 19.51B
IBIT iShares Bitcoin Trust

+1.45 (+4.17%)

USD 17.74B
CGABL The Carlyle Group Inc. 4.625% ..

+0.07 (+0.39%)

USD 16.14B
JEPQ JPMorgan Nasdaq Equity Premium..

-0.24 (-0.46%)

USD 11.10B
TBIL Rbb Fund Inc - Us Treasury 3 M..

+0.01 (+0.02%)

USD 2.97B
IBTE iShares iBonds Dec 2024 Term T..

+0.01 (+0.04%)

USD 2.89B
TDI Touchstone Dynamic Internation..

-0.03 (-0.11%)

USD 2.81B
IBTF iShares iBonds Dec 2025 Term T..

N/A

USD 2.19B
USCL iShares Climate Conscious & Tr..

-0.09 (-0.15%)

USD 2.01B

ETFs Containing CHAC-WT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A F
Risk Adjusted Return N/A N/A N/A N/A F
Market Capitalization N/A N/A N/A N/A F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike